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Purpose: The goal of this article was to review
infant physiology and its effects on the pharmacoki-
netic properties of antimicrobial agents.
Methods: A review of the drug development proc-
ess was performed. A literature search was conducted
on the pharmacokinetics of various antimicrobial
agents in infants.
Findings: The pharmacokinetic properties of anti-
microbial agents in infants are most often affected by
the renal maturation of premature infants. Hepatic
metabolism and volume of distribution play a com-
mon role as well.
Implications: The dosing and dosing intervals of
various medications were reviewed and compared
with details of adult dosing. It is vital to continue to
gather pharmacokinetic data in infants to ensure
adequate safety and dosing of medications. (Clin
Ther. 2016;38:1948–1960) & 2016 Elsevier HS Jour-
nals, Inc. All rights reserved.
Key words: Antibiotics, pharmacokinetics, infants,
antivirals, antifungals.INTRODUCTION
Antimicrobial agents are the most common medications
given to infants, both in the neonatal intensive care unit
and during the first month of life.1 Although progress is
being made, the majority of antimicrobial agents
prescribed to infants are still used “off label,” meaning
that they lack the dosing, safety, or efficacy data as
outlined in the label of the US Food and Drug
Administration (FDA). Off-label use of antimicrobialAccepted for publication June 30, 2016.
http://dx.doi.org/10.1016/j.clinthera.2016.06.017
0149-2918/$ - see front matter
& 2016 Elsevier HS Journals, Inc. All rights reserved.
1948agents in infants can lead to an unpredictable response
or morbidity due to their unique and evolving physiol-
ogy.2 Changes in liver metabolism, gastric absorption,
renal elimination, and distribution of such agents need
to be taken into account for infants.3 Over the past 10
years, substantial effort has been made to improve the
dosing, safety, and efficacy data of antimicrobial agents
for infants.
The present article reviews the process of drug
development with a special emphasis on infants, the
differences in pharmacokinetic (PK) properties be-
tween infants and adults, and dosing of commonly
used antimicrobial agents.MATERIALS AND METHODS
Infant Drug Development Process
The process of developing new medications in infants
is similar to the process in adults. For existing medi-
cations, there is a procedure whereby a sponsor may
receive a label change for children, including infants, as
long as certain conditions are met. This process is called
“extrapolation.”4 Two basic conditions must be met to
extrapolate a medication from adults to children. First,
children must have a similar disease progression and
second, children must have a similar response to the
medication, as established in adults. If these assumptions
are met, the medication then has the potential to
undergo either partial or full extrapolation depending
on other criteria. In full extrapolation, the exposure-
response to medications must be reasonably similar, and
the medication concentration must be measurable and
predictive of clinical response. If both criteria are met for
full extrapolation, a trial is conducted to select a doseScan the QR Code with your phone to obtain
FREE ACCESS to the articles featured in the
Clinical Therapeutics topical updates or text
GS2C65 to 64842. To scan QR Codes your
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safety trials are then performed at that dose. Partial
extrapolation can occur if it is either not reasonable to
assume a similar exposure-response in children or if the
medication concentration is not measurable or predictive
of clinical response. In partial extrapolation, dose-
ranging studies are performed to select the dose that
would achieve the target effect, and safety trials are then
performed at that dose. If assumptions for extrapolation
are not met, the medication must undergo a full
development process as noted earlier. Antimicrobial
agents are examples of a class of medications that can
often be extrapolated from adults to children because
the disease progression and response to the medication
are similar in adults and children.
To increase the safety and efficacy of medications in
children, the federal government has passed legislation
to address the gaps. In 1997, as part of the Food and
Drug Administration Modernization Act, a financial
incentive of an additional 6 months of exclusivity was
granted to pharmaceutical companies for patent-eligible
medications to encourage more pediatric-specific trials.
This action was then reauthorized with the Best Phar-
maceuticals for Children Act (BPCA), which also pro-
vided mechanisms to study medications in children, both
on- and off-patent. Due to the financial incentives of
BPCA, the Pediatric Research Equity Act was established
in 2003 to require pediatric assessments of any new
medication undergoing the labeling process. A pediatric
assessment includes ingredients (including excipients),
indications, dosing, and route of administration. The
next significant legal step was the Food and Drug
Administration Amendments Act of 2007, which reau-
thorized BPCA and the Pediatric Research Equity Act
and established a “Priority List” of pediatric therapeutics
that is to be reviewed every 3 years by the National
Institutes of Health and annually by the Eunice Kennedy
Shriver National Institute of Child Health and Human
Development. The Food and Drug Administration
Safety and Innovation Act of 2012 then made BPCA
permanent. It also required advisory by a neonatologist
to focus on the neonatal population given its high-risk
nature and changing physiology, both with gestational
age (GA) and postnatal age (PNA).
As a result of such legislation (specifically the
BPCA), the Pediatric Trials Network (www.pediatric
trials.org) was established and sponsored by the
Eunice Kennedy Shriver National Institute of Child
Health and Human Development. It is an alliance ofSeptember 2016clinical research sites around the United States; their
goal is to promote labeling for medications used in
pediatrics by studying dosing, efficacy, and safety.
General Principles of Clinical Pharmacology in
Infants
The clinical pharmacology of infants, including PK
properties, is often substantially different from
older children and adults. Absorption, distribution,
metabolism, and excretion are affected by age and
physiologic development. In infants, physiologic de-
velopment is dependent on GA and PNA. In this
section, we review some of the major differences
between infant and adult PK properties.
Absorption
The absorption of antimicrobial agents in infants
usually has less of an effect on PK outcomes because
many of these agents are administered intravenously.
The most common routes for absorption in infants are
via the intramuscular route and through gastric
absorption. Intramuscular administration of both
ampicillin and gentamicin is as effective as intravenous
administration.5,6 Therefore, these agents can be given
intramuscularly, although the intravenous route re-
mains the preferred method because repeated doses
are usually given.
Gastric absorption of antimicrobial agents in infants
has notable physiologic differences from the same
process in children and adults. Gastric emptying in
adults and children has an initial fast phase followed by
a slower phase.7 In contrast, infants have a slow, linear
gastric absorption that does not reach a similar adult
biphasic response until 6 to 8 months of age.8 Although
slower gastric emptying would theoretically make for
better gastric absorption, it tends to have minimal use in
sick infants.9 Because of incomplete gastric absorption,
the lack of data on bioavailability in infants, and the
requirement for certainty of antimicrobial agent
delivery, the usual route is intravenous.
Distribution
The PK properties of antimicrobial agents are also
affected by the volume of distribution. This parameter
is dependent on several characteristics of the agent,
including molecular size, ionization, and whether it is
water or lipid soluble. In infants, both the blood–brain
barrier and the relatively high body water content
affect distribution. The blood–brain barrier is not1949
Clinical Therapeuticsmature when infants are born, meaning that certain
antimicrobial agents can more easily penetrate it. As
an example, amphotericin B is an agent that achieves
higher central nervous system concentrations in in-
fants than in older children or adults.10 Infants’ heads
are disproportionally larger than adults compared
with the rest of the body, and infants thus have a
relatively larger central nervous system volume. The
relatively high body water content of both premature
and term infants generally increases the volume of
distribution of water-soluble drugs; water-soluble
drugs such as gentamicin therefore generally require
increased doses.11,12
Liver Metabolism
Metabolism commonly occurs in the liver and is
dependent on developmental changes in the newborn
infant. Metabolism in the liver depends on both blood
flow and enzyme activity, both of which are reduced
in children although they generally reach adult levels
by 1 year of age.13 The reactions that occur in the liver
during metabolism are also immature at birth. These
reactions include the cytochrome-P450 enzyme sys-
tem; some of these enzymes are present at birth, and
others change over time. Other processes include
methylation, acetylation, and glucuronidation.
Renal Excretion
The dosing of antimicrobial agents in infants often
depends on the renal system and its physiologic
changes through the infant’s first year of life. The
glomerular filtration rate (GFR) is extremely low at
birth and increases rapidly postnatally. The GFR is
even lower in premature infants because of decreased
nephron number, and nephron proliferation increases
rapidly between 32 and 36 weeks’ GA.14 Premature
infants have a slower rise in GFR over the first week
of life compared with term infants.15 GFR then
increases over the first 2 years of life to reach adult
values.16 Although GFR rises with increasing GA and
PNA in infants, it generally correlates more with
postmenstrual age (PMA; ie, GA plus PNA) rather
than PNA.17,18 Because aminoglycosides are com-
monly prescribed for newborns, an increase in GFR
improves clearance of these antimicrobial agents.19
Excretion of antimicrobial agents through the renal
system is also dependent on the function of the renal
tubules. The effects of tubular secretion are decreased
at birth and then increase over the first several months1950of life before reaching adult levels by 7 months of
age.20 The ability of the renal tubules to reabsorb
compounds can also be affected by a lower urinary
pH value that occurs in infants, specifically weak acids
and bases. Of note, it has been shown that patients
with low GFR can still have high clearance of
antimicrobial agents, such as imipenem, if tubular
secretion is relatively higher.21 In such patients, more
frequent dosing is needed.EXAMPLES OF ANTIMICROBIAL AGENTS
USED IN INFANTS
Ampicillin
Ampicillin is a β-lactam antimicrobial agent and the
most commonly used medication in infants in the
neonatal intensive care unit.1 Ampicillin is active
against group B streptococci, Listeria monocytogenes,
and some Escherichia coli isolates, all of which are
commonly seen infections in infants. Ampicillin is
renally eliminated and is therefore dependent on GFR.
Ampicillin is labeled by the FDA for use in pediatric
patients for respiratory, soft tissue, gastrointestinal,
and genitourinary infections, as well as bacterial
meningitis and septicemia. However, there is no
specific dosage for infants given on the label. Current
dosing recommendations for infants is stratified on the
basis of weight and PNA and based on limited data.22
To provide more data on dosing for ampicillin in
infants, investigators enrolled 73 infants stratified ac-
cording to both GA (before and after 34 weeks) and
PNA (before and after 7 days of life).23 The surrogate
pharmacodynamic target was time above the MIC of 2
and 8 μg/mL for Listeria species and E coli, respectively.
Using Monte Carlo simulations to compare dosing
between Neofax,24 the Harriet Lane Handbook,25 and
the proposed regimen, most premature infants needed
less frequent dosing; both PMA and creatinine were best
correlated with the clearance of ampicillin. The
proposed regimen accounts for infant renal maturation
and allows for less frequent dosing while still achieving
the desired therapeutic target in490% of patients. This
finding compares to more frequent dosing noted in
adults and older children.22,26,27 The stratified dosing
regimen is summarized in Table I.
Gentamicin
Gentamicin is an aminoglycoside antimicrobial
agent that is commonly used with ampicillin inVolume 38 Number 9
Table I. Comparison of infant and adult dosing for commonly used antibacterial agents.
Antibacterial
Agent Infant Dosing Adult Dosing125
Gestational
Age
Postnatal
Age
Postmenstrual
Age Dose
Dosing
Interval
Maintenance
Dose
Dosing
Interval
wk d wk mg/kg h mg h
Ampicillin23 r34 r7 50 12
8–28 75 12 1000–2000 4–6
435 o28 50 8
Gentamicin25 o32 r14 5 48
414 5 36
32–36 r7 4 36 4–7(mg/kg) 24
47 4 24
Z37 r28 4 24
Cefotaxime24 r28 r29 12
428 8
r14 30–36 12 1000–2000 8–12
414 50 8
r7 37–44 12
47 8
Meropenem59 o32 o14 20 12
Z14 20 8
Z32 o14 20 8 500–2000 8
Z14 30 8
Piperacillin-
tazobactam79
o30 100 8
30–35 80 6 3375 6
435 80 4 4500 6–8
Metronidazole87 15
(loading)
o34 7.5 12 1000
(loading)
34–40 7.5 8 500 6
440 7.5 6
Clindamycin93 r32 5 8
432–40 7 8 150–600 6–8
440 9 8
Vancomycin64,68 10
(loading)
500 6
10–15* 12 1000 12
*Continuous vancomycin option: 10 mg/kg loading dose followed by 25 to 30 mg/kg/d divided over 24 hours.
J.K. Johnson and M.M. Laughoninfants, and it is the second most commonly pre-
scribed agent in neonatal intensive care units.1 It has
in vitro synergism against gram-negative bacteria,September 2016specifically E coli, as well as activity against staph-
ylococcal species. The PK properties of gentamicin in
infants, children, and adults differ due to changing1951
Clinical Therapeuticsrenal physiology after birth.28,29 In addition to chang-
ing renal maturation, gentamicin dosing can also be
affected by weight, GA, and PNA, which all positively
influence clearance.30
Gentamicin is labeled by the FDA for use in neonatal
sepsis as well as serious bacterial infections of the central
nervous system, urinary tract, respiratory tract, and skin
and soft tissue, as well as serious intra-abdominal
infections. The current FDA label supports recommen-
dations for BID dosing in premature infants and infants
aged o1 week and TID dosing for infants aged 41
week.31 This guidance is in contrast to the
recommendations put forth by Neofax and Nelson's
Pocket Book of Pediatric Antimicrobial Therapy, which
are stratified according to PMA or GA with PNA,
respectively.24,25
Because of toxic effects on both the kidneys and the
ear, dosing of gentamicin has evolved over time from
a multiple daily dosing regimen to a once-daily dosing
regimen in pediatric populations and in adults.32–39
Meta-analysis has also revealed that with once-daily
dosing, efficacy is improved, and rates of ototoxicity
and nephrotoxicity are comparable.40 This outcome is
likely due to decreased accumulation of aminoglyco-
sides in the inner ear and renal tubules with once-daily
dosing.41,42
To achieve ideal concentrations, premature infants
need higher doses (up to 5 mg/kg) at more extended
intervals compared with term infants because of the
effects of GA and PNA on weight and renal mat-
uration.25,30 Extremely premature infants (ie, those
o28 weeks’ GA) also benefit from extended interval
dosing (up to every 48 hours) in which a dose is given
and a drug level is then checked before administration
of the second dose.43 Infants with sepsis may have a
larger volume of distribution and may also benefit
from higher doses to achieve adequate concent-
rations.44 In a setting in which extended interval
dosing is performed, this approach would likely
have minimal effect, as the dosing would be
readjusted with each level if needed.
Cefotaxime
Cefotaxime is a third-generation cephalosporin
used in infants for suspected or documented serious
bacterial infections from a gram-negative organism.
Cefotaxime is effective against ampicillin-resistant
strains of E coli. Cefotaxime also has sufficient
cerebrospinal fluid (CSF) penetration.45 However,1952this agent is associated with an increase in mortality
when used as a “rule out” sepsis at birth and an
increase in invasive candidiasis.46,47 Cefotaxime is
metabolized in the liver to its microbiologically
active metabolite desacetyl-cefotaxime and then ex-
creted in the urine as metabolized and unmetabolized
forms.48,49 Clearance of cefotaxime increases with
increasing PNA and GA.50,51
Cefotaxime is labeled by the FDA for use in both
the infant and pediatric populations. It is indicated in
the treatment of serious susceptible infections, includ-
ing those of the lower respiratory tract, genitourinary,
and central nervous system, as well as intra-
abdominal infections and bacteremia. For term infants
with susceptible infections (not including those of the
central nervous system), the cefotaxime dose is 100
mg/kg/d divided every 12 hours for the first week and
then 150 mg/kg/d divided every 8 hours there-
after.22,25 For premature infants, dosing is based on
PMA as well as PNA (Table I). When treating
meningitis, the dose is 225 to 300 mg/kg/d to
achieve adequate CSF concentrations.45,52
Meropenem
Meropenem is a broad-spectrum carbapenem com-
monly used to treat intra-abdominal infections in
infants.53 Given the high morbidity and mortality of
intra-abdominal infections (including necrotizing en-
terocolitis), and the wide range of organisms associ-
ated with these infections (including gram-positive,
gram-negative, and anaerobic organisms), clinicians
often use broad-spectrum antimicrobial agents.54,55
Meropenem is primarily cleared through the kidneys
in adults.56 Due to delayed maturation of the kidneys
in premature infants, meropenem clearance is higher
in term infants compared with premature infants.57
Meropenem is labeled for use in complicated skin
and soft tissue infections, complicated intra-
abdominal infections, and bacterial meningitis. When
treating skin and soft tissue infections, as well as
bacterial meningitis, the labeling provides guidance
for infants aged 43 months.58 To address the gap in
knowledge for those aged o3 months, investigators
performed a large multicenter trial to determine the
PK properties and safety profile of meropenem in
infants.59 They analyzed plasma meropenem
concentrations in 188 premature and term infants.
The trial stratified infants into groups based on GA
(o32 weeks and Z32 weeks) and PNA (o14 daysVolume 38 Number 9
J.K. Johnson and M.M. Laughonold and Z14 days old). Plasma meropenem
concentrations were monitored, and meropenem
clearance was associated with both serum creatinine
(reflecting renal function) and PMA. Investigators also
found that penetration of meropenem into the CSF
was 70%. A follow-up safety study also concluded
that there were no adverse events probably or defi-
nitely related to meropenem.60
Vancomycin
Vancomycin is a glycopeptide antibiotic used as
broad treatment for suspected or documented gram-
positive bacterial infections. Premature infants are at
high risk of infections from both late-onset sepsis and
secondary to central venous catheter exposure, and
clinicians often use vancomycin because of the risk of
coagulase-negative staphylococcal infections, which
are usually resistant to ampicillin or methicillin.61–63
Vancomycin is renally eliminated.
Vancomycin is FDA labeled for use in pediatric and
neonatal patients for the treatment of methicillin-resistant
Staphylococcus aureus infections of the lower respiratory
tract, bone, and skin and soft tissue. It is also labeled for
the treatment of endocarditis. Current FDA-labeled dos-
ing recommendations in infants are for an initial dose of
15 mg/kg followed by 10 mg/kg every 12 hours in the
first week of life and then every 8 hours thereafter. This
dosing regimen compares favorably to Neofax for term
infants although Neofax recommends more extended
intervals (8–18 hours) with more premature infants.24
However, because the clearance of vancomycin increases
with increasing PMA, monitoring of trough levels is
generally performed if the course is more than a few days.
Vancomycin is usually administered intermittently
(although continuous dosing has been used [discussed
later]) and the target trough concentrations are 15 to 20
mg/mL, although these targets are derived from adult
data.64 Guidelines from the Infectious Diseases Society of
America recommend similar trough targets in pediatric
patients.65 The current initial recommendations are
displayed in Table I, and close monitoring of trough
levels and adjusting them accordingly are often necessary.
Continuous infusion (with a constant infusion rate over
24 hours) of vancomycin has been reported in the
neonatal population.66–69 Continuous infusion may have
better bactericidal efficacy because vancomycin’s bacter-
icidal properties are time dependent.70 Kim et al71 found
that continuous vancomycin was as successful as
intermittent dosing in reaching target trough levels.September 2016However, safety and efficacy data do not currently exist
for the use of continuous vancomycin.
Piperacillin-Tazobactam
Piperacillin-tazobactam is an antimicrobial agent
that combines a β-lactam antibiotic with a β-lactamase
inhibitor. Piperacillin-tazobactam is used in compli-
cated intra-abdominal infections, such as necrotizing
enterocolitis, and gram-negative bacteremia.72
Piperacillin-tazobactam is primarily excreted by the
kidneys.73
Piperacillin-tazobactam is currently labeled by the
FDA for use in patients aged Z2 months with
susceptible infections, including appendicitis and peri-
tonitis. Current FDA-labeled dosing recommenda-
tions are 80-mg piperacillin/10-mg tazobactam per
kilogram every 8 hours for patients between 2 and 9
months of age. As such, there is no current approved
dosing recommendation for those aged o2 months,
including premature infants. As with vancomycin, it is
possible that the efficacy of piperacillin-tazobactam is
highest with extended and continuous infusions.74–77
Studies of piperacillin-tazobactam have been per-
formed by using scavenged blood, dried blood
spot samples, and plasma samples in premature
infants.78,79 In a study sponsored by the National
Institutes of Health, infants were stratified according
to GA and PNA by using dried blood spot samples
and plasma samples.79 Efficacy end points were
chosen and consistent with acceptable MIC levels
for Enterobacteriaceae and Pseudomonas aeruginosa
(16 μg/mL and 32 μg/mL, respectively). A PK model
was then developed based on these data and
compared with dosing from both Neofax and the
Harriet Lane Handbook. When comparing dosing
regimens, target attainment rates dropped to o40%
with increasing MIC 48 mg/mL using Neofax and
Harriet Lane Handbook dosing compared with the
dosing regimen based on the model (Table I).
Metronidazole
Metronidazole is a nitroimidazole antimicrobial
agent used in the treatment of anaerobic bacteremia
and complicated intra-abdominal infections such as
necrotizing enterocolitis.80,81 It is hepatically metabo-
lized by hydroxylation into its active metabolite,
hydroxy-metronidazole.82 Initial PK studies on
metronidazole found that hydroxylation occurred in
newborn infants who had received prenatal1953
Clinical Therapeuticsbetamethasone.83 Elimination is via renal excretion as
well as hepatic oxidation and glucuronidation.82
Metronidazole is FDA labeled for use in adult
patients in the treatment of intra-abdominal, skin
and soft tissue, gynecologic, central nervous system,
and lower respiratory tract infections, as well as
endocarditis and bacteremia. It is not FDA approved
for use in pediatric patients or infants and has
extensive off-label use.
Initial PK studies also revealed various dosing
intervals ranging from BID options to every other
day.83,84 More recent PK studies have used dried spot
sampling, scavenged blood samples, and timed blood
samples to analyze data.85–87 Dried spot sampling
found that the half-life decreases rapidly with increas-
ing PMA due to a 5-fold increase in clearance
compared with a 2.5-fold increase in volume of
distribution.85 A larger multicenter trial of infants
aged o32 weeks and o120 days’ PNA showed a
similar increase in clearance with increasing weight of
patients.86
A 2013 study used plasma and dried spot samples
to determine the parent/metabolite ratio for metroni-
dazole.87 Metronidazole weight-normalized clearance
increased and half-life decreased with increasing PNA.
A target trough concentration to obtain an MIC 48
mg/L against anaerobic bacteria was chosen. A dosing
regimen based on PMA is expected to achieve this
target in 80% of infants. Safety and efficacy for this
regimen are currently being evaluated as part of the
SCAMP (Antibiotic Safety in Infants With Compli-
cated Intra-Abdominal Infections) trial (clinicaltrials.
gov identifier NCT01994993).
Clindamycin
Clindamycin is a lincosamide antibiotic used in
the treatment of susceptible infections against staph-
ylococcal and streptococcal infections as well as
anaerobic infections. Due to its activity against
methicillin-resistant S aureus, its use in pediatric
patients has increased.88 Clindamycin is metabolized
in the liver, primarily by cytochrome P-450 3A4,
which undergoes ontogenic changes throughout the
first year of life.89 It is also highly protein bound,
specifically to α1-acid glycoprotein.90
Clindamycin is currently FDA labeled for the treat-
ment of lower respiratory tract, intra-abdominal,
gynecologic, bone, and skin and soft tissue infections,
as well as bacteremia caused by1954Staphylococcus, Streptococcus, and anaerobic species.
The labeled dose for infants aged o1 month is 15 to
20 mg/kg/d divided into 3 to 4 equal doses although
the labeling notes that a lower dose may be adequate
for smaller premature infants. This dosing regimen is
based on 2 studies that did not include premature
infants.91,92
To better estimate the PK properties of clindamycin
in infants, including premature infants, investigators
enrolled 35 infants in a PK study of clindamycin
(median GA, 28.8 weeks; median PNA, 9.5 days).93
The clearance of clindamycin was lower in infants
aged o32 weeks. The dosing from this study was
based on PMA (Table I). In a more recent study,
plasma samples were collected from premature infants
and combined with data from 2 previous trials.94 A
total of 62 infants o30 weeks’ GA (median GA, 28
weeks; median PNA, 17 days) were included.
Clearance was associated with PMA. The volume of
distribution was associated with plasma protein
concentrations. Dosing simulation was performed
based on the PMA-stratified regimen and resulted in
497% of simulated infants obtaining an MIC 40.12
μg/mL for S aureus. Investigators also tracked safety
and adverse events, none of which related to
clindamycin use.ANTIFUNGAL THERAPEUTICS
Invasive fungal infections, mainly caused by Candida
species, have high morbidity and mortality in infants.
Infants at risk for fungal infections include extremely
premature infants, term infants with indwelling cen-
tral venous catheters, or those receiving extracorpor-
eal membrane oxygenation. Common antifungal
agents include amphotericin B, fluconazole, and mi-
cafungin (Table II).
Amphotericin B is a fungicidal therapeutic agent
that is primarily protein bound and is transferred into
solid organs with minimal concentrations excreted in
the urine.95 It is currently FDA labeled for use in
pediatric patients aged 41 month with systemic
fungal infections. The current PK data reveal high
levels of interpatient variability, with lower serum
levels achieved at similar adult dosing.96,97 This
finding is believed to be due to a higher clearance in
infants. Linder et al98 studied 56 infants receiving
amphotericin B, liposomal amphotericin B, or
amphotericin B colloidal dispersion; none of theVolume 38 Number 9
Table II. Comparison of infant adult dosing for commonly used antifungal agents.
Antifungal Agent Infant Dosing Adult Dosing125
Dose Dosing Interval Maintenance Dose Dosing Interval
mg/kg h mg h
Fluconazole124 25(loading)
12 24 200–800 24
Micafungin109–113 10 24 100–150 24
J.K. Johnson and M.M. Laughoninfants had renal dysfunction, suggesting that this
condition is less likely to occur in infants compared
with adults. The current dosing recommendation for
amphotericin B is 1 to 1.5 mg/kg/d every 24 hours for
amphotericin B and 2.5 to 7 mg/kg/d every 24 hours
for the liposomal formulation, although more PK and
pharmacodynamics studies are needed.24
Fluconazole is a fungistatic therapeutic that inhibits
the cytochrome P-450 system; it synthesizes ergo-
sterol, a cell membrane component of fungi. It is
eliminated through the kidney. Fluconazole has a
large volume of distribution and increasing clearance
with both increasing PNA and PMA.99–102 However,
because steady state of the medication is often not
achieved until day 5 of therapy (due to its prolonged
half-life of 24 hours), a loading dose has been found
to be helpful at achieving therapeutic concentrations
earlier.101,103
Because invasive fungal infections cause high mor-
tality and morbidity, prophylactic administration of
fluconazole is used by some neonatal intensive care
units. Prophylactic fluconazole decreases the risk of
colonization and invasive fungal infection but hasTable III. Comparison of infant and adult dosing for co
unless otherwise indicated.
Antiviral Agent Infant Dosing
Postmenstrual Age Dose D
wk mg/kg
Acyclovir31,116 o30 20
430 20
Ganciciovir118–121 6
Valganciciovir (oral)122 16
September 2016little effect on mortality.104–106 Dosing for prophy-
laxis has been studied at both 3 mg/kg and 6 mg/kg
twice weekly, which is equivalent to an AUC of 50
and 100 mg h/L, respectively, and fluconazole con-
centrations ofZ2 and 4 μg/mL.107 Selection of dosing
for prophylaxis should therefore be dependent on
local Candida incidence and local MIC values.
Micafungin is an echinocandin that interrupts cell
wall biosynthesis and is highly protein bound.108 It is
often used in invasive Candida infections that are not
responsive to either amphotericin B or fluconazole. It
is dependent on hepatic metabolism and fecal
elimination for clearance. There are currently 5 PK
studies on micafungin in infants that have reported
efficacy at doses of 10 mg/kg/d.109–113ANTIVIRAL THERAPEUTIC AGENTS
Viral infections in infants, specifically those caused by
herpes simplex virus (HSV) and cytomegalovirus
(CMV), have long-term morbidity and increased
mortality in infants.114 Currently, HSV infections are
treated with acyclovir, and CMV infections are treatedmmonly used antiviral agents. Dosing is intravenous
Adult Dosing125
osing Interval Maintenance Dose Dosing Interval
h mg h
12
8 5–10 8
12 5(mg/kg) divided 12–24
12 900 divided 12–24
1955
Clinical Therapeuticswith ganciclovir. Both of these medications are
phosphorylated preferentially by kinases in the
respective viruses and inhibit viral DNA synthesis by
competitive inhibition of viral DNA polymerase.
Acyclovir is active against HSV-1 and HSV-2, as
well as varicella zoster virus. Its levels are dependent
on renal excretion, and CSF levels are approximately
one half of plasma levels.115 Clearance of acyclovir
increases with PMA due to renal maturation in
infants.116 Infants with disseminated HSV infections
treated with high doses of acyclovir (60 mg/kg/d) have
decreased mortality compared with those treated with
standard dosing (45 mg/kg/d).117 A PK study in
premature infants studied dosing intervals at a
uniform amount of 20 mg/kg per dose.116 According
to modeling from the study, those infants aged o30
weeks will achieve efficacy with every 12-hour dosing,
those aged 30 to o36 weeks with every 8-hour
dosing, and those aged 36 to 41 weeks with every
6-hour dosing (Table III). The proposed dosing
interval for infants of every 6 hours for infants aged
436 weeks has not yet had proper safety and
efficacious studies conducted and will need to be
validated before being formally recommended.
Valacyclovir, an oral pro-drug converted to acy-
clovir by the liver, has limited PK data available for
infants aged o1 month. Side effects include renal
toxicity and neutropenia and are monitored periodi-
cally with routine laboratory testing.
Ganciclovir and valganciclovir (the latter an oral
pro-drug converted to ganciclovir) are used to treat
CMV infection. Both forms are renally excreted, and
PK data have revealed that PNA, body surface area,
and sex do not have an effect once weight is taken into
account.118–121 For 6–mg/kg dosing, the AUC was
27 mg h/L, similar to adult data.118 Oral valgan-
ciclovir 16 mg/kg every 12 hours has also been shown
to have good bioavailability in infants, with the ability
to achieve optimal plasma levels.118,122 Treatment
with valganciclovir for 6 months, as opposed to 6
weeks, has been shown to improve audiology and
neurodevelopmental outcomes at 2 years.123CURRENT TRIALS OF ANTIMICROBIAL
AGENTS
Clinical trials of other medications in this population are
currently ongoing. Data have also been collected and
results are pending for rifampin and ticarcillin-1956clavulanate (clinicaltrials.gov identifier NCT01728363).
The SCAMP trial is currently collecting data with regard
to different combinations of antibiotics used in the
treatment of complicated intra-abdominal infections
and their safety. The 4 groups in the SCAMP trial are
ampicillin/gentamicin/metronidazole, ampicillin/gentami-
cin/clindamycin, gentamicin/piperacillin-tazobactam, and
standard of care antibiotics plus metronidazole. All
dosing is based on GA and PNA.SUMMARY AND FUTURE DIRECTIONS
Antimicrobial agents are commonly administered to
infants because bacterial, viral, and fungal infections
cause substantial morbidity and mortality. Although
progress is being made, the safest and most effective
dose for the majority of these agents is unknown in
infants. Because the physiology of infants, especially
premature infants, matures with age, the doses of
antimicrobial agents often change (usually increases)
with increasing PNA (or PMA). In addition, because
the maturation of drug-handling systems is different
from adults and older children, dosing cannot be
modeled or estimated from adults and older children
when applying it to premature and low birth weight
infants. Studies must be performed specifically on these
target populations to determine the appropriate dose.ACKNOWLEDGMENTS
Both authors contributed equally to the completion of
this article. Dr. Laughon is supported by the US
government for his work in pediatric and neonatal
clinical pharmacology (HHSN267200700051C [Prin-
cipal Investigator: Benjamin]), the National Institute
of Child Health and Human Development (K23
HD068497), and the National Heart, Lung, and
Blood Institute (R34 HL124038).CONFLICTS OF INTEREST
The authors have indicated that they have no conflicts
of interest regarding the content of this article.REFERENCES
1. Hsieh EM, et al. Medication use in the neonatal
intensive care unit. Am J Perinatol. 2014;31:811–821.
2. De Souza, et al. Off-label use and harmful potential of
drugs in a NICU in Brazil: a descriptive study. BMC
Pediatr. 2016;16:13.Volume 38 Number 9
J.K. Johnson and M.M. Laughon3. Kearns GL, et al. Developmental
pharmacology-drug disposition,
action, and therapy in infants
and children. N Engl J Med.
2003;349:1157–1167.
4. Dunne J, et al. Extrapolation of
adult data and other data in pedia-
tric drug-development programs.
Pediatrics. 2011;128:1242–1249.
5. Paisley JW, Smith AL, Smith DH.
Gentamicin in newborn infants.
Comparison of intramuscular and
intravenous administration. Am J
Dis Child. 1973;126:473–477.
6. Driessen OH, et al. Pharmacoki-
netic aspects of therapy with am-
picillin and kanamycin in newborn
infants. Eur J Clin Pharmacol.
1978;13:449–457.
7. Koren G. Therapeutic drug mon-
itoring principles in the neonate.
Clin Chem. 1997;43:222–227.
8. Butler DR, Kuhn RJ, Chandler MH.
Pharmacokinetics of anti-infective
agents in paediatric patients. Clin
Pharmacokinet. 1994;26:374–395.
9. McCracken GH, et al. Pharmaco-
logic evaluation of orally adminis-
tered antibiotics in infants and
children: effect of feeding on bio-
availability. Pediatrics. 1978;62:
738–743.
10. Cohen-Wolkowiez M, et al. Pedia-
tric antifungal agents. Curr Opin
Infect Dis. 2009;22:553–558.
11. Strolin BM, Baltes EL. Drug me-
tabolism and disposition in chil-
dren. Fundam Clin Pharmacol. 2003;17:
281–299.
12. McLeod HL, et al. Disposition of
antineoplastic agents in the very
young child. Br J Cancer Suppl.
1992;18:S23–S29.
13. Anderson GD, Lynn AM. Optimiz-
ing pediatric dosing: a develop-
mental pharmacologic approach.
Pharmacotherapy. 2009;29:680–690.
14. Black MJ, et al. When birth comes
early: effects on nephroge-
nesis. Nephrology (Carlton). 2013;18:
180–182.
15. Rhodin MM, et al. Human renal
function maturation: a quantitativeSeptember 2016description using weight and post-
menstrual age. Pediatr Nephrol.
2009;24:67–76.
16. Alcorn J, McNamara PJ. Ontogeny of
hepatic and renal systemic clearance
pathways in infants: part II. Clin
Pharmacokinet. 2002;41:1077–1094.
17. Leake RD, Trygstad CW. Glomer-
ular filtration rate during the pe-
riod of adaptation to extrauterine
life. Pediatr Res. 1977;11:959–962.
18. Arant BS Jr. Developmental patterns
of renal functional maturation com-
pared in the human neonate. J
Pediatr. 1978;92:705–712.
19. Zarowitz BJ, Robert S, Peterson EL.
Prediction of glomerular filtration
rate using aminoglycoside clear-
ance in critically ill medical pa-
tients. Ann Pharmacother. 1992;26:
1205–1210.
20. Strolin BM, Whomsley R, Baltes
EL. Differences in absorption, dis-
tribution, metabolism and excre-
tion of xenobiotics between the
paediatric and adult populations.
Expert Opin Drug Metab Toxicol.
2005;1:447–471.
21. Jacobs RF, et al. Renal clearance of
imipenem in children. Eur J Clin
Microbiol. 1984;3:471–474.
22. Kimberlin D.W., et al. Red Book,
30th Edition (2015): 2015 Report
of the Committee on Infectious
Diseases, 30th Edition. American
Academy of Pediatrics, Elk Grove
Village, IL.
23. Tremoulet A, et al. Characteriza-
tion of the population pharmaco-
kinetics of ampicillin in neonates
using an opportunistic study de-
sign. Antimicrob Agents Chemother.
2014;58:3013–3020.
24. Neofax. Truven Health Analytics,
v7.2.0.2016-Q2. Accessed June
28, 2016.
25. Nelson's Pocket Book of Pediatric
Antimicrobial Therapy. In: Bradley
JS, Nelson JD, Kimberlin DK, editors.
21st ed. American Academy of
Pediatrics, Elk Grove Village, IL; 2015.
26. Nahata MC, Vashi VI, Swanson
RN, Messig MA, Chung M.Pharmacokinetics of ampicillin
and sulbactam in pediatric pa-
tients. Antimicrob Agents Chemother.
1999;43:1225–1229.
27. Boe RW, et al. Serum levels of
methicillin and ampicillin in new-
born and premature infants in
relation to postnatal age. Pediatrics.
1967;39:194–201.
28. Giapros VI, et al. Renal function
and effect of aminoglycoside ther-
apy during the first ten days of life.
Pediatr Nephrol. 2003;18:46–52.
29. Medillin-Garibay SE, et al. Popu-
lation pharmacokinetics of genta-
micin and dosing optimization for
infants. Antimicrob Agents Chemo-
ther. 2015;59:482–489.
30. Fuchs A, et al. Population phar-
macokinetic study of gentamicin in
a large cohort of premature and
term neonates. Br J Clin Pharmacol.
2014;78:1090–1101.
31. Gentamicin [package insert]. Lake
Zurich, IL: Fresenius Kabi USA; 2013.
32. Best EJ, et al. Once-daily gentami-
cin in infants and children: a pro-
spective cohort study evaluating
safety and the role of therapeutic
drug monitoring in minimizing tox-
icity. Pediatr Infect Dis J. 2011;30:
827–832.
33. Ali MZ, Goetz MB. A meta-analysis
of the relative efficacy and toxicity
of single daily dosing versus multi-
ple daily dosing of aminoglycosides.
Clin Infect Dis. 1997;24:796–809.
34. Bailey TC, et al. A meta-analysis of
extended-interval dosing versus
multiple daily dosing of amino-
glycosides. Clin Infect Dis. 1997;24:
786–795.
35. Barza M, et al. Single or multiple
daily doses of aminoglycosides: a
meta-analysis. BMJ. 1996;312:338–
345.
36. Ferriols-Lisart R, Alos-Alminana
M. Effectiveness and safety of
once-daily aminoglycosides: a
meta-analysis. Am J Health Syst
Pharm. 1996;53:1141–1150.
37. Galloe AM, et al. Aminoglycosides:
single or multiple daily dosing? A1957
Clinical Therapeuticsmeta-analysis on efficacy and
safety. Eur J Clin Pharmacol. 1995;48:
39–43.
38. Hatala R, Dinh T, Cook DJ. Once-
daily aminoglycoside dosing in im-
munocompetent adults: a meta-
analysis. Ann Intern Med. 1996;124:
717–725.
39. Munckhof WJ, Grayson ML,
Turnidge JD. A meta-analysis of
studies on the safety and efficacy
of aminoglycosides given either
once daily or as divided doses.
J Antimicrob Chemother. 1996;37:
645–663.
40. Contopoulos-Ioannidis DG, et al.
Extended-interval aminoglycoside
administration for children: a
meta-analysis. Pediatrics. 2004;114:
e111–e118.
41. De Broe ME, Verbist L, Verpooten
GA. Influence of dosage schedule
on renal cortical accumulation of
amikacin and tobramycin in man.
J Antimicrob Chemother. 1991;27
(suppl C):41–47.
42. Tran Ba Huy P, Bernard P, Schacht
J. Kinetics of gentamicin uptake
and release in the rat: comparison
of inner ear tissues and fluids with
other organs. J Clin Invest. 1986;77:
1492–1500.
43. Alshaik B, et al. Extended interval
dosing of gentamicin in premature
neonates r 28-week gestation.
Acta Paediatr. 2012;101:1134–
1139.
44. Lingvall M, et al. The effect of
sepsis upon gentamicin pharma-
cokinetics in neonates. Br J Clin
Pharmacol. 2005;59:54–61.
45. Sullins AK, Abdel-Rahman SM.
Pharmacokinetics of antibacterial
agents in the CSF of children and
adolescents. Pediatr. Drugs. 2013;15:
93–117.
46. Clark RH, et al. Empiric use of
ampicillin and cefotaxime, com-
pared with ampicillin and genta-
micin, for neonates at risk for sepsis
is associated with an increased
risk of neonatal death. Pediatrics.
2006;117:67–74.195847. Cotten CM, et al. The association
of third-generation cephalosporin
use and invasive candidiasis in
extremely low birth- weight infants.
Pediatrics. 2006;118:717–722.
48. Lassman HB, Coombes JD. Me-
tabolism of cefotaxime: a review.
Diagn Microbiol Infect Dis. 1984;2:
3S–12S.
49. Kearns GL, Young RA. Pharmaco-
kinetics of cefotaxime and desace-
tylcefotaxime in the young. Diagn
Microbiol Infect Dis. 1995;22:97–
104.
50. Bertels RA, et al. Serum concen-
trations of cefotaxime and its me-
tabolite desacetyl-cefotaxime in
infants and children during contin-
uous infusion. Infection. 2008;36:
415–420.
51. Aujard Y, Brion F, Jacqz-Aigrain E,
et al. Pharmacokinetics of cefotax-
ime and desacetylecefotaxime in
the newborn. Diagn Microbiol Infect
Dis. 1989;12:87–91.
52. Stockmann C, et al. Considera-
tions in the pharmacologic treat-
ment and prevention of neonatal
sepsis. Paediatr Drugs. 2014;16:
67–81.
53. Pfaller MA, Jones RN. A review of
the in vitro activity of meropenem
and comparative antimicrobial age-
nts tested against 30,254 aerobic
and anaerobic pathogens isolated
worldwide. Diagn Microbiol Infect Dis.
1997;28:157–163.
54. Solomkin JS, et al. Diagnosis and
management of complicated
intra-abdominal infection in
adults and children: guidelines
by the Surgical Infection Society
and the Infectious Diseases Soci-
ety of America. Clin Infect Dis.
2010;50:133–164.
55. Neu J, Walker WA. Necrotizing
enterocolitis. N Engl J Med. 2011;
364:255–264.
56. Ljungberg B, Nislsson-Ehle I. Phar-
macokinetics of meropenem and
its metabolite in young and elderly
healthy men. Antimicrob Agents Che-
mother. 1992;36:1437–1440.57. van den Anker JN, et al. Merope-
nem pharmacokinetics in the new-
born. Antimicrob Agents Chemother.
2009;53:3871–3879.
58. Clark RH, et al. Reported medica-
tion use in the neonatal intensive
care unit: data from a large na-
tional data set. Pediatrics. 2006;117:
1979–1987.
59. Smith PB, et al. Population phar-
macokinetics of meropenem in
plasma and cerebrospinal fluid of
infants with suspected or compli-
cated intra-abdominal infections.
Pediatr Infect Dis J. 2011;30:844–
849.
60. Cohen-Wolkowiez M, et al. Safety
and effectiveness of meropenem in
infants with suspected or compli-
cated intra-abdominal infections.
Clin Infect Dis. 2012;55:1495–1502.
61. Stoll BJ, et al. Late-onset sepsis in
very low birth weight neonates: the
experiences of the NICHD Neo-
natal Research Network. Pediatrics.
2002;110:285–291.
62. Clark R, et al. Nosocomial infec-
tion in the NICU: a medical com-
plication or unavoidable problem.
J Perinatol. 2004;24:382–388.
63. Rubin LG, et al. Evaluation and
treatment of neonates with sus-
pected late-onset sepsis: a survey
of neonatologists’ practices. Pedia-
trics. 2002;110:e42.
64. Rybak M, et al. Therapeutic mon-
itoring of vancomycin in adult
patients: a consensus review of
American Society of Health-
System Pharmacists, the Infectious
Diseases Society of America, and
the Society of Infectious Diseases
Pharmacists. Am J Health Syst Pharm.
2009;66:82–98.
65. Liu C, et al. Clinical practice guide-
lines by the Infectious Diseases
Society of America for the treat-
ment of methicillin-resistant
Staphylococcus aureus infections
in adults and children. Clin Infect
Dis. 2011;52:285–292.
66. Patel AD, et al. Intermittent versus
continuous infusion of vancomycinVolume 38 Number 9
J.K. Johnson and M.M. Laughonin neonates. Arch Dis Child. 2012;
97:e20.
67. Pawlotsky F, et al. Constant rate of
infusion of vancomycin in prema-
ture neonates: a new dosage
schedule. Br J Clin Pharmacol.
1998;46:163–167.
68. Plan O, et al. Continuous-infusion
vancomycin therapy for preterm
neonates with suspected or docu-
mented gram-positive infections: a
new dosage schedule. Arch Dis
Child Fetal Neonatal Ed. 2008;93:
F418–F421.
69. Zhao W, et al. Vancomycin con-
tinuous infusion in neonates: dos-
ing optimisation and therapeutic
drug monitoring. Arch Dis Child.
2013;98:449–453.
70. Ackerman BH, Vannier AM, Eudy
EB. Analysis of vancomycin time-kill
studies with Staphylococcus species
by using a curve stripping program
to describe the relationship between
concentration and pharmacody-
namic response. Antimicrob Agents
Chemother. 1992;36:1766–1769.
71. Kim J, et al. Determination of
vancomycin pharmacokinetics in
neonates to develop practical ini-
tial dosing recommendations. Anti-
microb Agents Chemother. 2014;58:
2830–2840.
72. Berger A, et al. Safety evaluation of
piperacillin/tazobactam in very
low birth weight infants. J Chemo-
ther. 2004;16:166–171.
73. Sorgel F, Kinzig M. The chemistry,
pharmacokinetics and tissue distri-
bution of piperacillin/tazobactam.
J Antimicrob Chemother. 1993;31:
39–60.
74. Felton TW, et al. Population phar-
macokinetics of extended-infusion
piperacillin-tazobactam in hospi-
talized patients with nosocomial
infections. Antimicrob Agents Chemo-
ther. 2012;56:4087–4094.
75. Roberts JA, et al. First-dose
and steady-state population phar-
macokinetics and pharmacody-
namics of piperacillin by contin-
uous or intermittent dosing inSeptember 2016critically ill patients with sepsis. Int
J Antimicrob Agents. 2010;35:156–
163.
76. Shea KM, et al. Comparative phar-
macodynamics of intermittent and
prolonged infusions of piperacillin/
tazobactam using Monte Carlo
simulations and steady-state phar-
macokinetic data from hospital-
ized patients. Ann Pharmacother.
2009;43:1747–1754.
77. Cies JJ, et al. Population pharma-
cokinetics of piperacillin/tazobac-
tam in critically ill young children.
Pediatr Infect Dis J. 2014;33:168–
173.
78. Cohen-Wolkowiez M, et al. Popu-
lation pharmacokinetics of pipera-
cillin using scavenged samples
from preterm infants. Ther Drug
Monit. 2012;34:312–319.
79. Cohen-Wolkowiez M, et al. Devel-
opmental pharmacokinetics of pi-
peracillin and tazobactam using
plasma and dried blood spots
from infants. Antimicrob Agents Che-
mother. 2014;58:2856–2865.
80. Brook I. Bacteremia due to anae-
robic bacteria in newborns. J Peri-
natol. 1990;10:351–356.
81. Thompson AM, Bizzarro MJ. Ne-
crotizing enterocolitis in new-
borns: pathogenesis, prevention
and management. Drugs. 2008;68:
1227–1238.
82. Loft S, et al. Influence of dose and
route of administration on dispo-
sition of metronidazole and its
major metabolites. Eur J Clin Phar-
macol. 1986;30:467–473.
83. Jager-Roman E, et al. Pharmacoki-
netics and tissue distribution of
metronidazole in the newborn in-
fant. J Pediatr. 1982;100:651–654.
84. Upadhyaya P, Bhatnagar V, Basu
N. Pharmacokinetics of intrave-
nous metronidazole in neonates.
J Pediatr Surg. 1988;23:263–265.
85. Suyagh M, et al. Metronidazole
population pharmacokinetics in
preterm neonates using dried
blood-spot sampling. Pediatrics. 2011;
127:e367–e374.86. Cohen-Wolkowiez M, et al. Popu-
lation pharmacokinetics of metro-
nidazole evaluated using scav-
enged samples from preterm in-
fants. Antimicrob Agents Chemother.
2012;56:1828–1837.
87. Cohen-Wolkowiez M, et al. Deter-
mining population and develop-
mental pharmacokinetics of
metronidazole using plasma and
dried blood spot samples from
premature infants. Pediatr Infect
Dis J. 2013;32:956–961.
88. Herigon JC, Hersh AL, Gerber JS,
Zaoutis TE, Newland JG. Antibiotic
management of Staphylococcus
aureus infections in US children’s
hospitals, 1999-2008. Pediatrics.
2010;125. e1294-E1300.
89. Wynalda M, Hutzler J, Koets M. In
vitro metabolism of clindamycin in
human liver and intestinal micro-
somes. Drug Metab Dispos. 2003;31:
878–887.
90. Son DS, Osabe M, Shimoda M,
Kokue E. Contribution of alpha
1-acid glycoprotein to species dif-
ference in lincosamides-plasma
protein binding kinetics. J Vet Phar-
macol Ther. 1998;21:34–40.
91. Koren G, et al. Pharmacokinetics
of intravenous clindamycin in new-
born infants. Pediatr Pharmacol
(New York). 1986;5:287–292.
92. Bell MJ, et al. Pharmacokinetics of
clindamycin phosphate in the first
year of life. J Pediatr. 1984;105:
482–486.
93. Gonzalez D, et al. Use of opportun-
istic clinical data and a population
pharmacokinetic model to support
dosing of clindamycin for premature
infants to adolescents. Clin Pharmacol
Ther. 2014;96:429–437.
94. Gonzalez D, et al. Clindamycin
pharmacokinetics and safety in
preterm and term infants. Antimi-
crob Agents Chemother. 2016;60:
2888–2894.
95. Atkinson AJ, Bennet JE. Amphoter-
icin B pharmacokinetics in hu-
mans. Antimicrob Agents Chemother.
1978;13:271–276.1959
Clinical Therapeutics96. Starke JR, et al. Pharmacokinetics
of amphotericin B in infants and
children. J Infect Dis. 1987;155:
766–774.
97. Koren G, et al. Pharmacokinetics
and adverse effects of amphotericin
B in infants and children. J Pediatr.
1988;113:559–563.
98. Linder N, et al. Treatment of can-
didaemia in premature infants:
comparison of three amphotericin
B preparations. J Antimicrob Chemo-
ther. 2003;52:663–667.
99. Nahata MC, Tallian KB, Force RW.
Pharmacokinetics of fluconazole in
young infants. Eur. Drug Metab
Pharmacokinet. 1999;24:155–157.
100. Saxén H, Hoppu K, Pohjavuori M.
Pharmacokinetics of fluconazole in
very low birth weight infants during
the first two weeks of life. Clin Phar-
macol Ther. 1993;54:269–277.
101. Wade KC, et al. Population phar-
macokinetics of fluconazole in
young infants. Antimicrob Agents
Chemother. 2008;52:4043–4049.
102. Wenzl TG, et al. Pharmacokinetics of
oral fluconazole in premature infants.
Eur J Pediatr. 1998;157:661–662.
103. Piper L, et al. Fluconazole loading
dose pharmacokinetics and safety
in infants. Pediatr Infect Dis J. 2011;
30:375–378.
104. Benjamin DK, et al. Effect of flu-
conazole prophylaxis on candidia-
sis and mortality in premature
infants: a randomized controlled
trial. JAMA. 2014;311:1742–1749.
105. Manzoni P, et al. A multicenter,
randomized trial of prophylactic
fluconazole in preterm neonates.
N Engl J Med. 2007;356:2483–2495.
106. Cleminson J, Austin N, McGuire W.
Prophylactic systemic antifungal
agents to prevent mortality and
morbidity in very low birth weight
infants. Cochrane Database Syst Rev.
2015:10. CD003850.
107. Wade KC, et al. Fluconazole dosing
for the prevention or treatment of
invasive candidiasis in young in-
fants. Pediatr Infect Dis J. 2009;
28:717–723.1960108. Chen SC, Slavin MA, Sorrell TC.
Echinocandin antifungal drugs in
fungal infections: a comparison.
Drugs. 2011;71:11–41.
109. Benjamin DK, et al. Safety and
pharmacokinetics of repeat-dose
micafungin in young infants. Clin
Pharmacol Ther. 2010;87:93–99.
110. Heresi GP, et al. The pharmacoki-
netics and safety of micafungin, a
novel echinocandin, in premature
infants. Pediatr Infect Dis J.
2006;25:1110–1115.
111. Hope WW, et al. Population phar-
macokinetics of micafungin in neo-
nates and young infants. Antimicrob
Agents Chemother. 2010;54:2633–
2637.
112. Kawada M, et al. Pharmacokinetics
of prophylactic micafungin in very-
low-birth-weight infants. Pediatr In-
fect Dis J. 2009;28:840–842.
113. Smith PB, et al. Pharmacokinetics
of an elevated dosage of micafun-
gin in premature neonates. Pediatr
Infect Dis J. 2009;28:412–415.
114. Corey L, Wald A. Maternal and neo-
natal herpes simplex virus infections.
N Engl J Med. 2009;361:1376–1385.
115. Wagstaff AJ, Faulds D, Goa Kl.
Acyclovir: a reappraisal of its anti-
viral activity, pharmacokinetic
properties and therapeutic efficacy.
Drugs. 1994;47:153–205.
116. Sampson MR, et al. Population phar-
macokinetics of intravenous acyclovir
in preterm and term infants. Pediatr
Infect Dis J. 2014;33:42–49.
117. Kimberlin DW, et al. Safety and
efficacy of high-dose intravenous
acyclovir in the management of
neonatal herpes simplex virus
infections. Pediatrics. 2001;108:
230–238.118. Acosta EP, et al. Ganciclovir pop-
ulation pharmacokinetics in neo-
nates following intravenous
administration of ganciclovir and
oral administration of a liquid val-
ganciclovir formulation. Clin Phar-
macol Ther. 2007;81:867–872.
119. Trang JM, et al. Linear single-
dose pharmacokinetics of ganciclovir
in newborns with congenital cytome-
galovirus infections. NIAID Collabo-
rative Antiviral Study Group. Clin
Pharmacol Ther. 1993;53:15–21.
120. Zhou XJ, et al. Population pharma-
cokinetics of ganciclovir in newborns
with congenital cytomegalovirus in-
fections. NIAID Collaborative Anti-
viral Study Group. Antimicrob Agents
Chemother. 1996;40:2202–2205.
121. Whitley RJ, et al. Ganciclovir treat-
ment of symptomatic congenital
cytomegalovirus infection: results
of a phase II study. National In-
stitute of Allergy and Infectious
Diseases Collaborative Antiviral
Study Group. J Infect Dis. 1997;175:
1080–1086.
122. Kimberlin DW, et al. Pharmacoki-
netic and pharmacodynamic as-
sessment of oral valganciclovir in
the treatment of symptomatic con-
genital cytomegalovirus disease.
J Infect Dis. 2008;197:836–845.
123. Kimberlin DW, et al. Valganciclovir
for symptomatic congenital cyto-
megalovirus disease. N Engl J Med.
2015;372:933–943.
124. Turner K, et al. Fluconazole phar-
macokinetics and safety in prema-
ture infants. Curr Med Chem.
2012;19:4617–4620.
125. Lexicomp Onlines, Pediatric & Neo-
natal Lexi-Drugss, Hudson, Ohio:
Lexi-Comp, Inc; April 5, 2016.Address correspondence to: Jacob K. Johnson, MD, University of North
Carolina at Chapel Hill, Department of Pediatrics, 101 Manning Drive,
CB# 7596, Chapel Hill, NC 27599-7596. E-mail: jacob.johnson@
unchealth.unc.eduVolume 38 Number 9
